<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01216254</url>
  </required_header>
  <id_info>
    <org_study_id>NKEBN/219/2010</org_study_id>
    <nct_id>NCT01216254</nct_id>
  </id_info>
  <brief_title>Clinical Trial Comparing Outcomes of Breast Conserving Operations With Classic v High-frequency Electrocoagulation</brief_title>
  <official_title>Prospective, Randomized Clinical Trial Comparing Pain Sensation, Seroma Formation and Quality od Life Following BCT With SLND in Breast Cancer Patients Operated With Classic Versus High-frequency Electrocoagulation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Gdansk</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Gdansk</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the outcomes of breast conserving therapy operation
      depending on the type of surgical tool used: classic electrocoagulation with higher operative
      temperatures and high frequency electrocoagulation with lower operative temperatures. The
      investigators would assess the pain levels, length and amount of the lymphatic secretion as
      well as quality of life following breast conserving surgery.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Control</measure>
    <time_frame>From the day before surgery up to 12 weeks (+/-2days) after surgery</time_frame>
    <description>Pain assessment would be performed using Visual Analogue Scale (VAS) at the days 1-5, 10 (+/- 2), 20 (+/- 2), 30 (+/- 2), and 12 weeks (+/- 2 days). SF - MPQ questionnaire would be filled in on admission, 10th (+/- 2) post-operative day and 12 weeks (+/- 2 days)after surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL)</measure>
    <time_frame>From the day before surgery up to 12 weeks (+/-2days) after surgery</time_frame>
    <description>Pre-operative assessment of QoL would be performed by psychologist using questionnaires: CISS, HADS - M, Eysencka. Postoperative assessment of QoL would be performed using QLQ C30 and QLQ BR 23 questionnaires 12 weeks (+/- 2 days)after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of lymphatic secretion</measure>
    <time_frame>From the day before surgery up to 12 weeks (+/-2days) after surgery</time_frame>
    <description>Number of days of lymphatic secretion would be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of lymphatic secretion</measure>
    <time_frame>From the day before surgery up to 12 weeks (+/-2days) after surgery</time_frame>
    <description>Amount of lymphatic secretion would be measured until it stops on daily basis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Classic electrocoagulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm of the study where the classic low-frequency electrocoagulation is used during the operation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Frequency electrocoagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm of the study where the tested high-frequency electrocoagulation is used during the operation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>classic v high-frequency electrocoagulation</intervention_name>
    <description>During the BCT with SLND the investigators would use two types of electrocoagulation. The steps of the operation would remain the same in both arms, nevertheless the tool used would vary.</description>
    <arm_group_label>Classic electrocoagulation</arm_group_label>
    <arm_group_label>High Frequency electrocoagulation</arm_group_label>
    <other_name>Ellmann</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  female

          -  age 18-100

          -  breast cancer

          -  stage IIA and II B (cT1a-3; cN0-1; cM0)

          -  no previous breast surgery

          -  no previous cancer

          -  obtained informed consent

        Exclusion Criteria:

          -  stages I, III, IV

          -  localised breast infection

          -  previous breast surgery for any cause

          -  previous cancer

          -  no voluntary consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacek Zielinski, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Gdansk</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Janusz Jaskiewicz, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Medical University of Gdansk</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacek Zielinski, M.D., Ph.D.</last_name>
    <phone>+48583492440</phone>
    <email>jaziel@gumed.edu.pl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maciej Bobowicz, M.D.</last_name>
    <phone>+48608738614</phone>
    <email>mbobowicz@gumed.edu.pl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Surgical Oncology</name>
      <address>
        <city>Gdansk</city>
        <state>Pomorskie</state>
        <zip>80-211</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jacek Zielinski, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maciej Bobowicz, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Iwona Chruscicka, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Piotr Rak, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pawel Kabata, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Radoslaw Jaworski, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2010</study_first_submitted>
  <study_first_submitted_qc>October 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2010</study_first_posted>
  <last_update_submitted>January 30, 2012</last_update_submitted>
  <last_update_submitted_qc>January 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Gdansk</investigator_affiliation>
    <investigator_full_name>Jacek Zielinski</investigator_full_name>
    <investigator_title>Assistant Profesor</investigator_title>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>stage 2</keyword>
  <keyword>breast conserving therapy</keyword>
  <keyword>sentinel lymph node dissection</keyword>
  <keyword>high frequency electrocoagulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

